Does Rallies show Form 4 insider transactions for MBX?

Yes. Rallies tracks MBX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MBX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MBX. It does not provide personalized investment advice.

MBX (MBX Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

MBX Biosciences, Inc. Common Stock (MBX) is a publicly traded Healthcare sector company. As of May 20, 2026, MBX trades at $31.45 with a market cap of $1.47B and a P/E ratio of -13.25. MBX moved +3.31% today. Year to date, MBX is +7.23%; over the trailing twelve months it is +154.29%. Its 52-week range spans $4.81 to $45.85. Analyst consensus is strong buy with an average price target of $73.11. Rallies surfaces MBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MBX stock inside the company?

Recent MBX insider activity includes Azoulay Salomon sold 55.00K, Azoulay Salomon sold 15.00K, Azoulay Salomon sold 231, Hawryluk P. Kent sold 607, and Hawryluk P. Kent bought 18.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MBX Key Metrics

Key financial metrics for MBX
Metric	Value
Price	$31.45
Market Cap	$1.47B
P/E Ratio	-13.25
EPS	$-2.38
Dividend Yield	0.00%
52-Week High	$45.85
52-Week Low	$4.81
Volume	757.13K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-86.97M
Gross Margin	0.00%

Recent MBX Insider Trades

Azoulay Salomon sold 55.00K (~$2.11M) on May 8, 2026.
Azoulay Salomon sold 15.00K (~$574.61K) on May 8, 2026.
Azoulay Salomon sold 231 (~$6.82K) on May 6, 2026.
Hawryluk P. Kent sold 607 (~$17.93K) on May 6, 2026.
Hawryluk P. Kent bought 18.50K (~$525.66K) on Mar 13, 2026.

Latest MBX News

MBX Biosciences Phase 1 Data Shows 7% Weight Loss, Monthly Dosing Potential — May 11, 2026
MBX Biosciences Secures $440M Funding, Progresses Canvuparatide Phase 3 for Q3 Start — May 7, 2026
MBX Biosciences Appoints Soued as CCO with 160,000-Option Grant; Q2 Webinar Scheduled — May 7, 2026
MBX Biosciences Plans 160-Patient Phase 3 Trial of Weekly Canvuparatide in Q3 2026 — Mar 9, 2026
MBX Biosciences Raises Cash Runway to $460M and Plans Q2 Phase II Update — Mar 1, 2026

MBX Analyst Consensus

10 analysts cover MBX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $73.11.

Common questions about MBX

Who is trading MBX stock inside the company?: Recent MBX insider activity includes Azoulay Salomon sold 55.00K, Azoulay Salomon sold 15.00K, Azoulay Salomon sold 231, Hawryluk P. Kent sold 607, and Hawryluk P. Kent bought 18.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MBX?: Yes. Rallies tracks MBX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MBX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MBX. It does not provide personalized investment advice.